9 March 2016 - The Transparency Commission will consider the reimbursement of ceftolozane sulphate with tazobactam sodium (Zerbaxa), lumacaftor with ivacaftor (Orkambi), carfilzomib (Kyprolis), mepolizumab (Nucala) and tobramycin (Vantobra).

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-03/ordre_du_jour_ct_16032016.pdf [French]